MIA-RAB4B: A Potential Drug Target and Biomarker (G100529262)

Target Name: MIA-RAB4B

NCBI ID: G100529262

MIA-RAB4B

Other Name(s): MIA-RAB4B readthrough (NMD candidate) | RAB4B

MIA-RAB4B: A Potential Drug Target and Biomarker

MIA-RAB4B, a protein that belongs to the MIA (Mucin interacting adaptor) family, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its unique structure and subcellular localization make it an attractive target for small molecules, antibodies, or other therapeutic agents that can modulate its function and contribute to the development of personalized medicine.

MIA-RAB4B is a 21-kDa transmembrane protein that is expressed in various tissues and organs, including the brain, pancreas, heart, and gastrointestinal tract. Its primary function is to interact with extracellular matrix (ECM) components, such as cytoskeletal filaments and adhesion molecules, allowing it to regulate cell-cell and cell-ECM interactions. This protein plays a crucial role in cell signaling, embryonic development, tissue repair, and inflammation.

MIA-RAB4B has been implicated in various diseases and conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Its functions in these processes have been studied extensively, and its potential as a drug target has been evaluated using various experimental techniques.

In cancer, MIA-RAB4B has been shown to be involved in various signaling pathways, including cell proliferation, migration, and invasion. It has also been shown to promote the formation of cancer-initiating cells, such as melanoma cells. Therefore, targeting MIA-RAB4B with small molecules or antibodies has been considered as a potential strategy for cancer treatment.

In neurodegenerative diseases, MIA-RAB4B has been linked to the development and progression of various neurodegenerative disorders, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Its role in these processes has been studied extensively, and its potential as a drug target has been evaluated using various experimental techniques.

In autoimmune disorders, MIA-RAB4B has been shown to play a crucial role in the development and maintenance of autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, and guillain-Barre syndrome. Its functions in these processes have been studied extensively, and its potential as a drug target has been evaluated using various experimental techniques.

MIA-RAB4B has unique structural features that make it an attractive target for small molecules, antibodies, or other therapeutic agents. Its transmembrane structure and subcellular localization make it relatively stable in the cell, and its interaction with ECM components makes it relatively resistant to inhibition. Additionally, its broad expression pattern and ease of manipulation using various techniques make it an attractive target for drug development.

In conclusion, MIA-RAB4B is a protein with great potential as a drug target and biomarker for various diseases. Its unique structure and subcellular localization make it an attractive target for small molecules, antibodies, or other therapeutic agents that can modulate its function. Further studies are needed to fully understand its role in various diseases and to develop safe and effective drugs that can target MIA-RAB4B.

Protein Name: MIA-RAB4B Readthrough (NMD Candidate)

The "MIA-RAB4B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIA-RAB4B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets